265 related articles for article (PubMed ID: 23453242)
1. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
[TBL] [Abstract][Full Text] [Related]
2. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
Rey JB; Luria RB
J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
[TBL] [Abstract][Full Text] [Related]
3. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
4. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
5. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes.
Bidier M; Zschoche C; Gholam P; Enk AH; Hadaschik EN
Acta Derm Venereol; 2012 Jul; 92(4):408-9. PubMed ID: 22278389
[No Abstract] [Full Text] [Related]
6. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.
Efthimiou P; Blanco M
Semin Arthritis Rheum; 2008 Dec; 38(3):188-94. PubMed ID: 18221985
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema].
Lopez L; Wierzbicka-Hainaut E; Villers A; Guillet G
Ann Dermatol Venereol; 2009 Apr; 136(4):330-6. PubMed ID: 19361699
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
Baglama Š; Trčko K
Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
[TBL] [Abstract][Full Text] [Related]
10. [Dermato-neuro syndrome during scleromyxedema: efficacy of plasmapheresis and intravenous immunoglobulin].
Charles S; Hainaut E; Cante V; Valette C; Levillain P; Guillet G
Ann Dermatol Venereol; 2014; 141(8-9):523-7. PubMed ID: 25209816
[TBL] [Abstract][Full Text] [Related]
11. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Wang SS; Chen QY; Xiang LH
Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
[TBL] [Abstract][Full Text] [Related]
12. Scleromyxedema.
Hummers LK
Curr Opin Rheumatol; 2014 Nov; 26(6):658-62. PubMed ID: 25215418
[TBL] [Abstract][Full Text] [Related]
13. An unusual presentation of scleromyxedema as inflammatory myopathy.
Vysakha KV; Poyuran R; Nair SS; Nair M
Acta Myol; 2019 Mar; 38(1):13-16. PubMed ID: 31309176
[TBL] [Abstract][Full Text] [Related]
14. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare.
Rongioletti F; Cozzani E; Parodi A
J Cutan Pathol; 2010 Oct; 37(10):1084-7. PubMed ID: 19638067
[TBL] [Abstract][Full Text] [Related]
15. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
[TBL] [Abstract][Full Text] [Related]
16. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).
Blum M; Wigley FM; Hummers LK
Medicine (Baltimore); 2008 Jan; 87(1):10-20. PubMed ID: 18204366
[TBL] [Abstract][Full Text] [Related]
17. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
Brunet-Possenti F; Hermine O; Marinho E; Crickx B; Descamps V
J Am Acad Dermatol; 2013 Aug; 69(2):319-20. PubMed ID: 23866873
[No Abstract] [Full Text] [Related]
18. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature.
Sroa N; Campbell S; Bechtel M
J Drugs Dermatol; 2010 Mar; 9(3):263-5. PubMed ID: 20232589
[TBL] [Abstract][Full Text] [Related]
19. Scleromyxedema with histology resembling granuloma annulare.
Mullangi S; Granter SR; Laubach JP; Lipworth AD
Dermatol Online J; 2014 Dec; 21(3):. PubMed ID: 25780962
[TBL] [Abstract][Full Text] [Related]
20. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.
Delyon J; Bézier M; Rybojad M; Brière J; Validire P; Bagot M; Janin A; Battistella M
Virchows Arch; 2013 Jun; 462(6):679-83. PubMed ID: 23681113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
